Can-Fite BioPharma's Partner Reports Positive Study Results of Piclidenoson in Dogs With Osteoarthritis

MT Newswires Live10-18

Can-Fite BioPharma (CANF) said Friday that its veterinary partner Vetbiolix reported positive final results from the clinical study of Piclidenoson in dog patients with osteoarthritis, with the study achieving its primary and secondary endpoints.

"The final data from the osteoarthritis study are very encouraging," said Sari Fishman, vice president of business Development at Can-Fite. "This veterinary indication offers Can-Fite the opportunity to get Piclidenoson onto the market faster to benefit canine, and potentially contribute to near-term revenues."

Vetbiolix has exercised its option for an in-license agreement with Can-Fite and will pay an upfront payment, milestone payments and royalties upon regulatory approval, bringing projected income of $325 million to Can-Fite over the next 10 years, the firm said.

Price: 2.76, Change: +0.06, Percent Change: +2.33

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment